NCT07135466View on ClinicalTrials.gov

A Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor in Patients With CD22 B-cell Malignancies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

January 1, 2028

Conditions

B Cell Malignancies

Interventions

OTHER

CD22 CAR-T cells

CD22 CAR-T cells

Trial Locations (1)

Unknown

Sheba Medical Center, Ramat Gan

All Listed Sponsors

lead

Sheba Medical Center

OTHER_GOV